Why it might be worthwhile for investors to get started now

Biontech employees in the laboratory

The research pipeline gives rise to higher valuations for the stock.

(Photo: dpa)

Frankfurt With their successful vaccines and promising research projects, the vaccine developers Biontech, Moderna and Co. rose to new market stars almost overnight. Between the beginning of 2020 and August 2021, their ratings increased significantly more than tenfold.

But since the middle of the year there has been some disillusionment. Investors had to learn that this sector is not immune to risks and uncertainties either. Almost all vaccine values ​​have now lost more than 50 percent from their top ratings.

Last Friday alone, Biontech and Moderna lost around a fifth of their value after Pfizer presented surprisingly strong test results for a new type of Covid drug. A few days earlier, Moderna had caused considerable disappointment with a reduced sales forecast. Curevac’s vaccine failed completely at the first attempt. Novavax is struggling with persistent production problems.

Read on now

Get access to this and every other article in the

Web and in our app for 4 weeks free of charge.

Further

Read on now

Get access to this and every other article in the

Web and in our app for 4 weeks free of charge.

Further

.
source site